[Granulocyte colony stimulating factor (G-CSF) in treatment of patients with HIV-associated mucocutaneous Kaposi sarcoma. Successful use in virus and drug-induced leukopenia].
Three patients with HIV-associated Kaposi sarcoma were treated with human recombinant granulocyte colony stimulating factor (G-CSF). They had all developed leucopenia during treatment with recombinant interferon-alpha-2a, in two cases combined with vincristine. In all three patients, there was an obvious rapid stimulation after s.c. injection of 300 or 150 micrograms G-CSF per day; the white blood count reached normal values within only a few days and partial transformation to leucocytosis took place. After discontinuation of G-CSF, leucocyte counts regressed rapidly to pretreatment levels. A dose of 150 micrograms of G-CSF twice to three times per week proved to be sufficient to keep the white blood cell count in the normal range allowing the treatment necessary for Kaposi sarcoma. G-CSF therapy had no serious side effects. One of the patients developed a tumour-like infiltration in his left upper jaw, which histologically simulated Burkitt's lymphoma and which regressed spontaneously after discontinuation of the G-CSF therapy. G-CSF plays an important role in the treatment of patients with HIV-associated Kaposi sarcoma and enables combined treatment with zidovudine, interferon, and cytostatic drugs.
D000328:Adult; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D015658:HIV Infections / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007279:Injections, Subcutaneous; D007958:Leukocyte Count / Q000187:drug effects; D007970:Leukopenia / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa / Q000473:pathology; D009062:Mouth Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D012514:Sarcoma, Kaposi / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D012867:Skin / Q000473:pathology; D012878:Skin Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D015215:Zidovudine / Q000008:administration & dosage
D016179:Granulocyte Colony-Stimulating Factor; D015215:Zidovudine
Granulozyten-Koloniestimulierender Faktor (G-CSF) in der Behandlung von Patienten mit HIV-assoziiertem mukokutanem Kaposi-Sarkom. Erfolgreicher Einsatz bei virus- bzw. medikamenteninduzierter Leukopenie.